Taiwan FDA registration 1adf9dcafebe615d9fd0408fa26715db
INNO-LiPA HLA-C Amplification
TW: 因諾-立帕人類白血球抗原擴增試劑組-C位點
Taiwan·Risk Class 2·MD·FUJIREBIO EUROPE N.V.·Registered Apr 22, 2015 – Apr 22, 2025CancelledRegistration details
- Analysis ID
- 1adf9dcafebe615d9fd0408fa26715db
- License Form
- Ministry of Health Medical Device Import No. 027217
- Customs Code
- DHA05602721702
Company information
- Manufacturer
- FUJIREBIO EUROPE N.V.
- Manufacturer Country
- Belgium
- Authorized Representative
- Taiwan Fu Pharmaceutical Co., Ltd
Product details
- Product Type (Level 1)
- B Hematology and pathology devices
- Product Type (Level 2)
- B0001 Human leukocyte antigen segmentation board
- Import Information
- Imported from abroad
Dates and status
- Registration Date
- Apr 22, 2015
- Expiry Date
- Apr 22, 2025
- Cancellation Date
- Oct 28, 2022
Cancellation information
- Status
- Logged out
- Reason
- 公司歇業
About this record
Access comprehensive regulatory information for INNO-LiPA HLA-C Amplification in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 1adf9dcafebe615d9fd0408fa26715db and manufactured by FUJIREBIO EUROPE N.V.. The authorized representative in Taiwan is Taiwan Fu Pharmaceutical Co., Ltd.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices